Key facts
- This page summarizes Lori Teranishi's Form 3 filing for Emmaus Life Sciences, Inc. (EMMA).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 24 Jan 2022, 12:05.
Lori Teranishi - 06 Jan 2022 Form 3 Insider Report for Emmaus Life Sciences, Inc. (EMMA)
- Reporting relationship
- Director
- Issuer ticker
- EMMA
- Reported as of
- 06 Jan 2022
- Net transaction value
- $0
- Reporting owner signature
- Lori Teranishi
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Lori Teranishi filed Form 3 for Emmaus Life Sciences, Inc. (EMMA) on 24 Jan 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EMMA
holding
Common stock, $0.001 par value
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 18,161
- Date
- 06 Jan 2022
- Ownership
- By IQ PR, Inc.
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
IQ PR, Inc, is a California corporation of which Ms. Teranishi is the sole shareholder and director.